Cargando…

Progression in multiple sclerosis is associated with low endogenous NCAM

Multiple sclerosis (MS) is a CNS disorder characterized by demyelination and neurodegeneration. Although hallmarks of recovery (remyelination and repair) have been documented in early MS, the regenerative capacity of the adult CNS per se remains uncertain with the wide held belief that it is either...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gnanapavan, Sharmilee, Ho, Peggy, Heywood, Wendy, Jackson, Sam, Grant, Donna, Rantell, Khadija, Keir, Geoff, Mills, Kevin, Steinman, Lawrence, Giovannoni, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298029/ https://www.ncbi.nlm.nih.gov/pubmed/23495921 http://dx.doi.org/10.1111/jnc.12236

Ejemplares similares

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
por: Adams, Ashok, et al.
Publicado: (2022)

A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
por: Gnanapavan, Sharmilee, et al.
Publicado: (2014)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Distinctive PSA-NCAM and NCAM Hallmarks in Glutamate-Induced Dendritic Atrophy and Synaptic Disassembly
por: Podestá, María Fernanda, et al.
Publicado: (2014)

No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation
por: Keddie, Stephen, et al.
Publicado: (2018)

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains
por: Saxena, Gauri K., et al.
Publicado: (2020)

Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β
por: Lee, Paul R., et al.
Publicado: (2017)

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
por: Reyes, Saúl, et al.
Publicado: (2020)

Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy
por: Mahler, Christoph, et al.
Publicado: (2020)

Binding properties of detergent-solubilized NCAM
Publicado: (1990)

The Hidden Side of NCAM Family: NCAM2, a Key Cytoskeleton Organization Molecule Regulating Multiple Neural Functions
por: Parcerisas, Antoni, et al.
Publicado: (2021)

Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases
por: Mukadam, Naaheed, et al.
Publicado: (2014)

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
por: Lim, Ee Tuan, et al.
Publicado: (2004)

Are NCAM deficient mice an animal model for schizophrenia?
por: Albrecht, Anne, et al.
Publicado: (2012)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
por: Bar-Or, Amit, et al.
Publicado: (2020)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Expression of NCAM containing VASE in neurons can account for a developmental loss in their neurite outgrowth response to NCAM in a cellular substratum
Publicado: (1994)

Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis
por: Wagley, Sariqa, et al.
Publicado: (2018)

Intercellular space is affected by the polysialic acid content of NCAM
Publicado: (1992)

Specific alteration of NCAM-mediated cell adhesion by an endoneuraminidase
Publicado: (1985)

Neural cell adhesion molecule (NCAM) association with PKCβ(2) via βI spectrin is implicated in NCAM-mediated neurite outgrowth
por: Leshchyns'ka, Iryna, et al.
Publicado: (2003)

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement
por: Hegen, Harald, et al.
Publicado: (2022)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

Identification of NCAM that interacts with the PHE-CoV spike protein
por: Gao, Wei, et al.
Publicado: (2010)

NCAM1 Polysialylation: The Prion Protein's Elusive Reason for Being?
por: Mehrabian, Mohadeseh, et al.
Publicado: (2016)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)
por: Bar-Or, Amit, et al.
Publicado: (2021)

Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials
por: Lanz, Tobias V, et al.
Publicado: (2023)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Cell surface dynamics and cellular distribution of endogenous FcRn
por: D’Hooghe, Lena, et al.
Publicado: (2017)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

NCAM promotes assembly and activity-dependent remodeling of the postsynaptic signaling complex
por: Sytnyk, Vladimir, et al.
Publicado: (2006)

Cosignaling of NCAM via lipid rafts and the FGF receptor is required for neuritogenesis
por: Niethammer, Philipp, et al.
Publicado: (2002)

Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma
por: Korja, Miikka, et al.
Publicado: (2009)

The interplay between NCAM and FGFR signalling underlies ovarian cancer progression
por: Colombo, N, et al.
Publicado: (2011)

Low prefrontal PSA-NCAM confers risk for alcoholism-related behavior
por: Barker, Jacqueline M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_heb3hpmp3aqs24bo1kfbncus07